Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Aug;18(8):e13360.
doi: 10.1111/irv.13360.

Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024

Liliana Antunes  1 , Clara Mazagatos  2   3 , Iván Martínez-Baz  3   4 , Reinout Naesens  5 , Maria-Louise Borg  6 , Goranka Petrović  7 , Terra Fatukasi  8 , Ligita Jancoriene  9 , Ausenda Machado  10 , Beatrix Oroszi  11 , Petr Husa  12 , Mihaela Lazar  13 , Ralf Dürrwald  14 , Jennifer Howard  1 , Aryse Melo  15 , Gloria Pérez-Gimeno  2   3 , Jesús Castilla  3   4 , Eva Bernaert  5 , Aušra Džiugytė  6 , Zvjezdana Lovrić Makarić  7 , Margaret Fitzgerald  8 , Auksė Mickienė  16 , Verónica Gomez  10 , Gergő Túri  11 , Lenka Součková  12 , Alexandru Marin  17 , Kristin Tolksdorf  18 , Nathalie Nicolay  19 , Angela M C Rose  1 ; European Hospital Vaccine Effectiveness Group
Affiliations
Multicenter Study

Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024

Liliana Antunes et al. Influenza Other Respir Viruses. 2024 Aug.

Abstract

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Keywords: COVID‐19 XBB.1.5 vaccine; Europe; SARS‐CoV‐2 hospitalisation; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Aukse Mickiene has received a grant for the Independent Investigator Initiated Research (Project Code/PO/Tracking Number WI236259; Grant ID#53233947); Pfizer R&D Investigator‐Initiated Research program (https://www.pfizer.com/science/collaboration/investigator‐initiated‐research) for the scientific project ‘A prospective study on the long‐term outcome and pathogenesis of tick‐borne encephalitis’ and a Grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infectious Diseases of the Brain (ESGIB); sponsorship for participation in the international scientific conferences by MSD, Pfizer, Abbvie, Janssen, payments for lectures in local scientific conferences and consultation fees from GSK, Sanofi, Pfizer and E‐visit.

Ligita Jancoriene has received honoraria fees for lectures from Pfizer, Viatris and Swixx Biopharma.

All other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Countries and study sites included in the VEBIS hospital network, Europe, 05 October 2023–14 January 2024.VEBIS: Vaccine Effectiveness, Burden and Impact Studies Twelve participating sites: Belgium (BE), Croatia (HR), Czechia (CZ), Germany (DE), Hungary (HU), Ireland (IE), Lithuania (LT), Malta (MT), Navarre region, Spain (NA), Portugal (PT), Romania (RO) and Spain (ES). Included in this analysis: BE, HR, IE, LT, MT, NA and ES.
See this image and copyright information in PMC

References

    1. European Medicines Agency , “COVID‐19 Medicines,” https://www.ema.europa.eu/en/human‐regulatory‐overview/public‐health‐thr....
    1. European Centre for Disease Prevention and Control (ECDC) , “Interim COVID‐19 Vaccination Coverage in the EU/EEA During the 2023–24 Season Campaigns,” (2024), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/interim‐covid‐19‐vaccina....
    1. European Centre for Disease Prevention and Control (ECDC) , “Communicable Disease Threats Report, 17–23 December 2023, Week 51,” (2023), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/communicable‐disease‐thr....
    1. European Centre for Disease Prevention and Control (ECDC) , “Core Protocol for ECDC Studies of COVID‐19 Vaccine Effectiveness Against Hospitalisation With Severe Acute Respiratory Infection, Laboratory‐Confirmed With SARS‐CoV‐2 or With Seasonal Influenza—Version 3.0,” (2024), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/core‐protocol‐ecdc‐studi....
    1. Peralta‐Santos A., Assessment of COVID‐19 Surveillance Case Definitions and Data Reporting in the European Union. Briefing Requested by the ENVI Committee (Brussels: European Parliament, 2020), http://www.europarl.europa.eu/RegData/etudes/BRIE/2020/652725/IPOL_BRI(2....

Publication types

Substances

LinkOut - more resources